For research use only. Not for therapeutic Use.
LY3023414 (also known as Pilaralisib)（Cat No.:I001489）is a potent, oral, dual inhibitor of PI3K and mTOR, targeting key nodes of the PI3K/Akt/mTOR pathway involved in cell growth, survival, and metabolism. By inhibiting both PI3K and mTORC1/2, LY3023414 effectively blocks tumor cell proliferation, induces apoptosis, and reduces tumor progression, making it a promising candidate for cancer therapy. It has shown efficacy in various cancers, including solid tumors and hematological malignancies, particularly those with aberrant PI3K signaling. LY3023414 is a valuable tool for understanding the therapeutic potential of dual PI3K/mTOR pathway inhibition.
| Catalog Number | I001489 |
| CAS Number | 1386874-06-1 |
| Synonyms | (S)-8-(5-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-(2-methoxypropyl)-3-methyl-1H-imidazo[4,5-c]quinolin-2(3H)-one |
| Molecular Formula | C23H26N4O3 |
| Purity | ≥95% |
| Target | Cell Cycle/DNA Damage |
| Solubility | 10 mM in DMSO |
| Storage | Store at -20℃ |
| IUPAC Name | 8-[5-(2-hydroxypropan-2-yl)pyridin-3-yl]-1-[(2S)-2-methoxypropyl]-3-methylimidazo[4,5-c]quinolin-2-one |
| InChI | InChI=1S/C23H26N4O3/c1-14(30-5)13-27-21-18-9-15(16-8-17(11-24-10-16)23(2,3)29)6-7-19(18)25-12-20(21)26(4)22(27)28/h6-12,14,29H,13H2,1-5H3/t14-/m0/s1 |
| InChIKey | ACCFLVVUVBJNGT-AWEZNQCLSA-N |
| SMILES | C[C@@H](CN1C2=C3C=C(C=CC3=NC=C2N(C1=O)C)C4=CC(=CN=C4)C(C)(C)O)OC |
| Reference | </br>1:PI3K/mTOR Dual Inhibitor, LY3023414, Demonstrates Potent Antitumor Efficacy Against Esophageal Adenocarcinoma in a Rat Model. Zaidi AH, Kosovec JE, Matsui D, Omstead AN, Raj M, Rao RR, Biederman RW, Finley GG, Landreneau RJ, Kelly RJ, Jobe BA.Ann Surg. 2016 Jul 29. [Epub ahead of print] PMID: 27471841 </br>2:Characterization of LY3023414, a Novel PI3K/mTOR Dual Inhibitor Eliciting Transient Target Modulation to Impede Tumor Growth. Smith MC, Mader MM, Cook JA, Iversen P, Ajamie R, Perkins E, Bloem L, Yip YY, Barda DA, Waid PP, Zeckner DJ, Young DA, Sanchez-Felix M, Donoho GP, Wacheck V.Mol Cancer Ther. 2016 Oct;15(10):2344-2356. Epub 2016 Jul 20. PMID: 27439478 |
